Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project.
Maniscalco GT, Brescia Morra V, Florio C, Lus G, Tedeschi G, Cianfrani M, Docimo R, Miniello S, Romano F, Sinisi L, Spitaleri DLA, Longo G, Trama U, Triassi M, Fasm Group, Scavone C, Capuano A. Maniscalco GT, et al. Among authors: docimo r. Pharmaceuticals (Basel). 2020 Dec 15;13(12):466. doi: 10.3390/ph13120466. Pharmaceuticals (Basel). 2020. PMID: 33333889 Free PMC article.
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience.
D'Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G, Valentino P, Buccafusca M, Cottone S, Salemi G, Ragonese P, Bossio RB, Docimo R, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F. D'Amico E, et al. Among authors: docimo r. Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404. doi: 10.1177/1756286418796404. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 30210582 Free PMC article.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Resting-State Functional Correlates of Social Cognition in Multiple Sclerosis: An Explorative Study.
Bisecco A, Altieri M, Santangelo G, Di Nardo F, Docimo R, Caiazzo G, Capuano R, Pappacena S, d'Ambrosio A, Bonavita S, Trojsi F, Cirillo M, Esposito F, Tedeschi G, Gallo A. Bisecco A, et al. Among authors: docimo r. Front Behav Neurosci. 2020 Feb 6;13:276. doi: 10.3389/fnbeh.2019.00276. eCollection 2019. Front Behav Neurosci. 2020. PMID: 32116584 Free PMC article.
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Lepore V, et al. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. Eur J Neurol. 2021. PMID: 33058344
130 results